Deregulation of microRNA expression in thyroid neoplasias

[1]  Domenico Coppola,et al.  MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. , 2016, The Journal of Biological Chemistry.

[2]  H. Moch,et al.  Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. , 2013, Thyroid : official journal of the American Thyroid Association.

[3]  H. M. Ahmad,et al.  MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. , 2013, Carcinogenesis.

[4]  Jingqing Yang,et al.  MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene , 2013, Oncogene.

[5]  S. Vacher,et al.  microRNA expression profile in a large series of bladder tumors: Identification of a 3‐miRNA signature associated with aggressiveness of muscle‐invasive bladder cancer , 2013, International journal of cancer.

[6]  Rounak Nassirpour,et al.  miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells , 2013, PloS one.

[7]  E. Rego,et al.  Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia , 2013, Experimental Hematology & Oncology.

[8]  K. Goryca,et al.  microRNAs in uterine sarcomas and mixed epithelial–mesenchymal uterine tumors: a preliminary report , 2013, Tumor Biology.

[9]  S. Zhong,et al.  miR-221/222: promising biomarkers for breast cancer , 2013, Tumor Biology.

[10]  C. Croce,et al.  Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status , 2013, PLoS genetics.

[11]  H. Zhang,et al.  Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma , 2013, OncoTargets and therapy.

[12]  A. Carè,et al.  The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway , 2013, International journal of cancer.

[13]  T. Hijikata,et al.  MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties. , 2013, Experimental cell research.

[14]  Kuender D Yang,et al.  Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. , 2013, The Journal of clinical endocrinology and metabolism.

[15]  M. Cannataro,et al.  In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma , 2013, Oncotarget.

[16]  Y. Dang,et al.  Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro , 2013, BMC Cancer.

[17]  William P Schiemann,et al.  TGF-β upregulates miR-181a expression to promote breast cancer metastasis. , 2013, The Journal of clinical investigation.

[18]  M. Gazouli,et al.  Expression of MicroRNAs in Patients With Pancreatic Cancer and Its Prognostic Significance , 2013, Pancreas.

[19]  F. Consorti,et al.  HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. , 2012, Oncology reports.

[20]  J. Błasiak,et al.  The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. , 2012, Acta biochimica Polonica.

[21]  J. Tobias,et al.  MicroRNA expression profiles of seminoma from paraffin-embedded formalin-fixed tissue , 2012, Virchows Archiv.

[22]  C. Croce,et al.  Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXYD5 (Dysadherin) gene. , 2012, The Journal of clinical endocrinology and metabolism.

[23]  Sung-Chou Li,et al.  Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer. , 2012, Oncology reports.

[24]  A. Pinchera,et al.  MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration. , 2012, European journal of endocrinology.

[25]  M. Rugge,et al.  MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. , 2012, Thyroid : official journal of the American Thyroid Association.

[26]  G. Melino,et al.  MicroRNA-191 triggers keratinocytes senescence by SATB1 and CDK6 downregulation , 2012, Biochemical and biophysical research communications.

[27]  M. Guerrero,et al.  MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer , 2012, Cancer.

[28]  Lei Han,et al.  High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma , 2012, Journal of Translational Medicine.

[29]  N. Seki,et al.  Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. , 2012, International journal of oncology.

[30]  C. Kang,et al.  miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. , 2012, Oncology reports.

[31]  Tao Jiang,et al.  Circulating microRNAs in cancer: origin, function and application , 2012, Journal of Experimental & Clinical Cancer Research.

[32]  E. Kure,et al.  Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing , 2012, PloS one.

[33]  N. Chegini,et al.  Endometrial miR-181a and miR-98 expression is altered during transition from normal into cancerous state and target PGR, PGRMC1, CYP19A1, DDX3X, and TIMP3. , 2012, The Journal of clinical endocrinology and metabolism.

[34]  F. Yu,et al.  Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[35]  M. Caligiuri,et al.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. , 2012, Blood.

[36]  A. Fusco,et al.  Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. , 2012, The Journal of clinical endocrinology and metabolism.

[37]  R. Giffard,et al.  miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. , 2012, Mitochondrion.

[38]  C. Croce,et al.  miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ , 2012, Oncogene.

[39]  M. Gariboldi,et al.  miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation , 2012, Molecular Cancer Research.

[40]  Subbaya Subramanian,et al.  Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma , 2012, Laboratory Investigation.

[41]  C. Croce,et al.  miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222 , 2012, Oncogene.

[42]  Ricardo Henao,et al.  Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma. , 2012, Journal of molecular endocrinology.

[43]  Y. Hseu,et al.  Generation of reactive oxygen species mediates butein-induced apoptosis in neuroblastoma cells , 2012, Oncology reports.

[44]  N. Seki,et al.  Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. , 2012, Biochemical and biophysical research communications.

[45]  Huiling He,et al.  MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases. , 2012, Thyroid : official journal of the American Thyroid Association.

[46]  R. Stephens,et al.  MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer , 2011, Nucleic acids research.

[47]  Xiuping Liu,et al.  Functional analysis of microRNAs in human hepatocellular cancer stem cells , 2011, Journal of cellular and molecular medicine.

[48]  Luigi Atzori,et al.  MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer , 2011, Clinical Cancer Research.

[49]  J. Sun,et al.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature Medicine.

[50]  J. Santini,et al.  MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. , 2011, Endocrine-related cancer.

[51]  David J Munroe,et al.  miRNA signature associated with outcome of gastric cancer patients following chemotherapy , 2011, BMC Medical Genomics.

[52]  D. Frezzetti,et al.  The microRNA-Processing Enzyme Dicer Is Essential for Thyroid Function , 2011, PloS one.

[53]  T. Jiang,et al.  Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. , 2011, Oncology reports.

[54]  Chin-Tarng Lin,et al.  MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells , 2011, Journal of Biomedical Science.

[55]  N. Guevara,et al.  Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland? , 2011, Endocrine-related cancer.

[56]  G. Chiappetta,et al.  miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. , 2011, The Journal of clinical endocrinology and metabolism.

[57]  Ya-Ni Tsai,et al.  The manipulation of miRNA-gene regulatory networks by KSHV induces endothelial cell motility. , 2011, Blood.

[58]  M. Toyota,et al.  Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. , 2011, Cancer research.

[59]  George A Calin,et al.  MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer , 2011, Genome Medicine.

[60]  R. Bourgon,et al.  miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer , 2011, Science Signaling.

[61]  C. Croce,et al.  A TSH-CREB1-microRNA loop is required for thyroid cell growth. , 2011, Molecular endocrinology.

[62]  Y. Chen,et al.  miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. , 2011, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[63]  A. Fusco,et al.  MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. , 2011, The Journal of clinical endocrinology and metabolism.

[64]  Alessandra Carè,et al.  Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma , 2011, Pigment cell & melanoma research.

[65]  Ru-Fang Yeh,et al.  TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer , 2011, Science Signaling.

[66]  Y. Asmann,et al.  miRNA Expression in Colon Polyps Provides Evidence for a Multihit Model of Colon Cancer , 2011, PloS one.

[67]  A. Gill,et al.  MicroRNA Profiling of Sporadic and Hereditary Medullary Thyroid Cancer Identifies Predictors of Nodal Metastasis, Prognosis, and Potential Therapeutic Targets , 2011, Clinical Cancer Research.

[68]  M. Nikiforova,et al.  MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma , 2011, Annals of Surgical Oncology.

[69]  Pei Wang,et al.  miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. , 2011, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[70]  E. Ross.  Gαq and Phospholipase C-β: Turn On, Turn Off, and Do It Fast , 2011, Science Signaling.

[71]  S. Hurtley.  Time for a Pause , 2011, Science Signaling.

[72]  V. Orlando,et al.  Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. , 2011, The Journal of clinical endocrinology and metabolism.

[73]  Maria Kafousi,et al.  MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer , 2011, Cell cycle.

[74]  M. Odenthal,et al.  Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors. , 2011, International journal of oncology.

[75]  Wei Wang,et al.  MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma , 2011, Acta Pharmacologica Sinica.

[76]  M. Ceccarelli,et al.  Upregulation of miR-21 by Ras in vivo and its role in tumor growth , 2011, Oncogene.

[77]  M. Farace,et al.  NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells , 2011, Nucleic acids research.

[78]  K. Junker,et al.  Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma , 2011, World Journal of Urology.

[79]  R. Dahiya,et al.  MicroRNAs 221/222 and Genistein-Mediated Regulation of ARHI Tumor Suppressor Gene in Prostate Cancer , 2010, Cancer Prevention Research.

[80]  R. Govindan,et al.  Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[81]  R. Elkon,et al.  A Pumilio-induced RNA structure switch in p27-3′ UTR controls miR-221 and miR-222 accessibility , 2010, Nature Cell Biology.

[82]  J. Cheng,et al.  MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma , 2010, Molecular Cancer.

[83]  H. Lodish,et al.  Distinct roles for miR‐1 and miR‐133a in the proliferation and differentiation of rhabdomyosarcoma cells , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[84]  N. Rosenfeld,et al.  Accurate molecular classification of renal tumors using microRNA expression. , 2010, The Journal of molecular diagnostics : JMD.

[85]  Johan Hansson,et al.  MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. , 2010, The Journal of investigative dermatology.

[86]  H. Dralle,et al.  Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas , 2010, Oncogene.

[87]  Muneesh Tewari,et al.  MiR‐221 and MiR‐222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival , 2010, Genes, chromosomes & cancer.

[88]  W. Filipowicz,et al.  Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.

[89]  C. Croce,et al.  MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. , 2010, Journal of the National Cancer Institute.

[90]  Sven Rahmann,et al.  Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma , 2010, Nucleic acids research.

[91]  G. Ferrari,et al.  MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. , 2010, Blood.

[92]  A. Fusco,et al.  Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. , 2010, European journal of cancer.

[93]  G. Cammarata,et al.  Differential expression of specific microRNA and their targets in acute myeloid leukemia , 2010, American journal of hematology.

[94]  Wei Zhu,et al.  MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. , 2010, Oncology reports.

[95]  Jianjun Chen,et al.  MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. , 2010, Blood cells, molecules & diseases.

[96]  Giancarlo Troncone,et al.  Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. , 2010, Genes & cancer.

[97]  A. Leonardi,et al.  Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a. , 2010, The Journal of clinical endocrinology and metabolism.

[98]  C. Croce,et al.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. , 2009, Cancer cell.

[99]  K. Ghoshal,et al.  TGFβ mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3 , 2009, Oncogene.

[100]  J. Qu,et al.  MicroRNA-1/206 Targets c-Met and Inhibits Rhabdomyosarcoma Development* , 2009, The Journal of Biological Chemistry.

[101]  Gian Luca Grazi,et al.  MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality , 2009, Clinical Cancer Research.

[102]  G. Kristiansen,et al.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.

[103]  X. Wang,et al.  Identification of microRNA‐181 by genome‐wide screening as a critical player in EpCAM–positive hepatic cancer stem cells , 2009, Hepatology.

[104]  C. Scholz,et al.  Expression of microRNA‐221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence , 2009, International journal of cancer.

[105]  C. Kang,et al.  Analysis of miR-221 and p27 expression in human gliomas. , 2009, Molecular medicine reports.

[106]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[107]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[108]  I. Rigoutsos.  New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. , 2009, Cancer research.

[109]  Myles Brown,et al.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. , 2009, Cancer research.

[110]  Kari Stefansson,et al.  Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations , 2009, Nature Genetics.

[111]  Michael A. Beer,et al.  Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation , 2009, Proceedings of the National Academy of Sciences.

[112]  Kedar S Vaidya,et al.  Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. , 2009, Cancer research.

[113]  K. Jażdżewski,et al.  Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer , 2009, Proceedings of the National Academy of Sciences.

[114]  A. Farcomeni,et al.  MicroRNA profiling in human medulloblastoma , 2009, International journal of cancer.

[115]  G. Crabtree,et al.  Understanding the Words of Chromatin Regulation , 2009, Cell.

[116]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[117]  Giovanni Vanni Frajese,et al.  The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice , 2008, PloS one.

[118]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[119]  Junxia Zhang,et al.  hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells , 2008, Brain Research.

[120]  Anna M. Krichevsky,et al.  miR-21: a small multi-faceted RNA , 2008, Journal of cellular and molecular medicine.

[121]  M. F. Shannon,et al.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. , 2008, Cancer research.

[122]  C. Croce,et al.  MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.

[123]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[124]  R. Stephens,et al.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.

[125]  Thomas D. Schmittgen,et al.  Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. , 2008, Cancer research.

[126]  T. Fahey,et al.  MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma , 2008, Modern Pathology.

[127]  C. Croce,et al.  MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer , 2008, Oncogene.

[128]  M. Ringel,et al.  Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. , 2008, Endocrinology and metabolism clinics of North America.

[129]  H. Namba,et al.  Oncogenic role of miR‐17‐92 cluster in anaplastic thyroid cancer cells , 2008, Cancer science.

[130]  Barbara Jarzab,et al.  Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma , 2008, Proceedings of the National Academy of Sciences.

[131]  T. Brabletz,et al.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells , 2008, EMBO reports.

[132]  G. Tseng,et al.  MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. , 2008, The Journal of clinical endocrinology and metabolism.

[133]  S. Kauppinen,et al.  LNA-mediated microRNA silencing in non-human primates , 2008, Nature.

[134]  C. Burge,et al.  Identification of let-7-regulated oncofetal genes. , 2008, Cancer research.

[135]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[136]  J. Dopazo,et al.  Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information , 2008, Oncogene.

[137]  G. Wakabayashi,et al.  Downregulation of miR‐138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines , 2008, Cancer science.

[138]  A. Fusco,et al.  Roles of HMGA proteins in cancer , 2007, Nature Reviews Cancer.

[139]  C. Croce,et al.  Specific microRNAs are downregulated in human thyroid anaplastic carcinomas , 2007, Oncogene.

[140]  Stijn van Dongen,et al.  miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..

[141]  Patricia Soteropoulos,et al.  MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. , 2007, Cancer research.

[142]  Y. Pekarsky,et al.  The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. , 2007, Best practice & research. Clinical haematology.

[143]  C. Croce,et al.  MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. , 2007, Endocrine-related cancer.

[144]  R. Moon,et al.  High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. , 2007, Endocrinology.

[145]  F. Slack,et al.  The let-7 microRNA represses cell proliferation pathways in human cells. , 2007, Cancer research.

[146]  Giovanni Vanni Frajese,et al.  miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1* , 2007, Journal of Biological Chemistry.

[147]  Stephen R. Master,et al.  Differential Expression of miRNAs in Papillary Thyroid Carcinoma Compared to Multinodular Goiter Using Formalin Fixed Paraffin Embedded Tissues , 2007, Endocrine pathology.

[148]  Birgit Samans,et al.  MYCN regulates oncogenic MicroRNAs in neuroblastoma , 2007, International journal of cancer.

[149]  Anindya Dutta,et al.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. , 2007, Genes & development.

[150]  S. Lowe,et al.  Role of the chromobox protein CBX7 in lymphomagenesis , 2007, Proceedings of the National Academy of Sciences.

[151]  O. Sheils,et al.  Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model , 2007, Molecular cancer.

[152]  Daniel Chourrout,et al.  Genome Regulation by Polycomb and Trithorax Proteins , 2007, Cell.

[153]  H. Aburatani,et al.  Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. , 2006, Gene.

[154]  O. Sheils,et al.  Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model , 2006, Molecular Cancer.

[155]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[156]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[157]  Stefano Volinia,et al.  MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  C. Eng,et al.  A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. , 2006, The Journal of clinical endocrinology and metabolism.

[159]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[160]  C. Croce,et al.  MicroRNA deregulation in human thyroid papillary carcinomas. , 2006, Endocrine-related cancer.

[161]  S. Asa,et al.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.

[162]  Brian S. Roberts,et al.  The colorectal microRNAome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[163]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[164]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[165]  C. Croce,et al.  The role of microRNA genes in papillary thyroid carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[166]  C. Croce,et al.  MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[167]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[168]  M. Santoro,et al.  Mutation of the PIK3CA gene in anaplastic thyroid cancer. , 2005, Cancer research.

[169]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[170]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[171]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[172]  G. Viglietto,et al.  A new mechanism of BRAF activation in human thyroid papillary carcinomas. , 2005, The Journal of clinical investigation.

[173]  M. Nikiforova,et al.  Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. , 2005, The Journal of clinical investigation.

[174]  A. Leonardi,et al.  Oncogenic and Anti-apoptotic Activity of NF-κB in Human Thyroid Carcinomas* , 2004, Journal of Biological Chemistry.

[175]  M. Santoro,et al.  Dysfunction of the RET receptor in human cancer. , 2004, Cellular and molecular life sciences : CMLS.

[176]  S. Hirohashi,et al.  Dysadherin Expression Facilitates Cell Motility and Metastatic Potential of Human Pancreatic Cancer Cells , 2004, Cancer Research.

[177]  M. Gariboldi,et al.  Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer , 2004, Oncogene.

[178]  C. Croce,et al.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[179]  M. Kruhøffer,et al.  Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas , 2004, Oncogene.

[180]  B. Giepmans.  Gap junctions and connexin-interacting proteins. , 2004, Cardiovascular research.

[181]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[182]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[183]  T. Dwight,et al.  Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[184]  V. Trovisco,et al.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.

[185]  Yuri E Nikiforov,et al.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[186]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[187]  M. Hirokawa,et al.  Observer Variation of Encapsulated Follicular Lesions of the Thyroid Gland , 2002, The American journal of surgical pathology.

[188]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[189]  Dillwyn Williams.  Cancer after nuclear fallout: lessons from the Chernobyl accident , 2002, Nature Reviews Cancer.

[190]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[191]  C. J. Chen,et al.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. , 2000, Science.

[192]  B. Spiegelman,et al.  PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma , 2000 .

[193]  G. Viglietto,et al.  PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1 , 2000, Oncogene.

[194]  A. Abbruzzese,et al.  Familial papillary thyroid microcarcinoma: a new clinical entity , 1999, The Lancet.

[195]  G. Botti,et al.  Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. , 1998, Cancer research.

[196]  M. Greene,et al.  The Concise Handbook of Family Cancer Syndromes , 1998 .

[197]  D. Kutler,et al.  Poorly Differentiated Insular Thyroid Carcinoma , 1998, Acta Cytologica.

[198]  M. P. Miano,et al.  Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression , 1997, Oncogene.

[199]  A. Fusco,et al.  Transformation of thyroid epithelium is associated with loss of c-kit receptor. , 1995, Cancer research.

[200]  M. Borrello,et al.  Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas , 1995, Journal of endocrinological investigation.

[201]  M. Pierotti,et al.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. , 1993, The Journal of clinical investigation.

[202]  T. Seyama,et al.  Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. , 1992, Cancer research.

[203]  M. Parmentier,et al.  Thyroid adenocarcinomas secondary to tissue-specific expression of simian virus-40 large T-antigen in transgenic mice. , 1991, Endocrinology.

[204]  S. Rubin,et al.  Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. , 1990, Molecular endocrinology.

[205]  B. Caillou,et al.  Presence of mutations in all three ras genes in human thyroid tumors. , 1990, Oncogene.

[206]  J. Rosai,et al.  Poorly differentiated (“insular”) thyroid carcinoma: A reinterpretation of Langhans' “wuchernde Struma” , 1984, The American journal of surgical pathology.

[207]  H. Moch,et al.  MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. , 2013, The Journal of clinical endocrinology and metabolism.

[208]  M. Rugge,et al.  PDCD4 expression in thyroid neoplasia , 2012, Virchows Archiv.

[209]  Shadan Ali,et al.  Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. , 2010, American journal of translational research.

[210]  M. Schott.  RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact , 2010 .

[211]  M. Schott.  Loss of the CBX7 Gene Expression Correlates with a Highly Malignant Phenotype in Thyroid Cancer , 2009 .

[212]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[213]  S. Asa,et al.  Thyroid gland: International case conference , 2002, Endocrine pathology.

[214]  A. Sakamoto,et al.  Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. , 2000, Pathology, research and practice.

[215]  K. Ain.  Anaplastic thyroid carcinoma: a therapeutic challenge. , 1999, Seminars in surgical oncology.

[216]  S. Asa,et al.  The demise of follicular carcinoma of the thyroid gland. , 1994, Thyroid : official journal of the American Thyroid Association.

[217]  J. Fagin,et al.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. , 1993, The Journal of clinical investigation.

[218]  R. Prentice,et al.  Radiation exposure and thyroid cancer incidence among Hiroshima and Nagasaki residents. , 1982, National Cancer Institute monograph.

[219]  W. F. Sheldon,et al.  Thyroid carcinoma in atomic bomb survivors Hiroshima and Nagasaki,. , 1969, American journal of epidemiology.